Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02728830 · ClinicalTrials.gov registry record · Early Phase 1
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
A Early Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by AA Secord.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT02728830 is a Early Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer that has completed, run by AA Secord. The registered enrollment target is 39 participants, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02728830, a Early Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, has completed, sponsored by AA Secord.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The ultimate goal of the study is to identify potential biomarkers, immune gene expression signatures, and co-stimulatory pathways that may be used to understand the effect of immune checkpoint inhibitors on gynecologic cancers.
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (1)
North Carolina
- Duke Cancer Institute - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-06 |
| Est. Completion | 2022-01-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02728830
The ClinicalTrials.gov registry entry for NCT02728830 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (85% lower). The listed sponsor is AA Secord, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02728830 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02728830 about?
NCT02728830 is a clinical study titled "A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers". The ultimate goal of the study is to identify potential biomarkers, immune gene expression signatures, and co-stimulatory pathways that may be used to understand the effect of immune checkpoint inhibitors on gynecologic cancers.
What is the current status of trial NCT02728830?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2016-06. Estimated completion is 2022-01-31.
What conditions does trial NCT02728830 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Epithelial Ovarian Cancer, Peritoneal Cancer, Gynecologic Neoplasms, Uterine Endometrial Cancer.
What interventions are being tested in trial NCT02728830?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02728830?
This trial is sponsored by AA Secord, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02728830 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Aspirin to Improve Immunological Features of Ovarian Tumors
RECRUITING · Early Phase 1
-
Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube
ACTIVE NOT RECRUITING · Early Phase 1
-
Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer
COMPLETED · Early Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.